Dispatches from Korea

Inside Celltrion: a biosimilar success story built on landfill

By Dan Stanton

29-Aug-2016 - Last updated on 30-Aug-2016 at 12:56 GMT

Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'

Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.

Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'

Related news

Related products

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Learn more about KLEPTOSE® BioPharma for your protein stability challenges

Roquette Pharma Solutions | 14-Jun-2019 | Case Study

Therapeutic proteins are inherently unstable and sensitive to temperature change, shearing, shaking, solvents, ionic strength, purity, protein concentration,...